Introduction: Targeted axillary dissection (TAD) was designed for nodal staging in cN+ breast cancer (BC) patients submitted to neoadjuvant therapy (NAT). A recent study questioned the need to mark suspicious nodes pre-NAT. Methods: cT1-4 N1-2 BC patients scheduled for NAT were selected for retrospective appraisal. Patients were divided according with SLNB/TAD and ycN0/ycN+ status. Detection rate (DR), concorda...